IDYA241220C30000
- 0.99
- 0.000.00%
IDEAYA Biosciences Newsroom
Wolfe's Most Shorted 'Hit List' – FSLR, BE, WBA, SJM
Ideaya Biosciences Inc. (IDYA): Among the NASDAQ Stocks With Biggest Upside Potential According to Analysts
Stephens Initiates IDEAYA Biosciences(IDYA.US) With Buy Rating, Announces Target Price $51
Stephens & Co. Initiates Coverage On IDEAYA Biosciences With Overweight Rating, Announces Price Target of $51
Express News | IDEAYA Biosciences Appoints Stu Dorman as Chief Commercial Officer
Press Release: IDEAYA Biosciences Appoints Stu Dorman as Chief Commercial Officer
Jim Cramer Says This Tobacco Stock Is 'Undervalued' But He's Not Recommending It
Mizuho Securities Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating
IDEAYA Biosciences Announces Participation in Jefferies London Healthcare Conference and Plans for Investor R&D Day
Biocytogen Pharmaceuticals Grants Worldwide License for Anti-Tumor Therapy
BeiGene (02315.HK) nominated IDEAYA first-in-class potential B7H3/PTK7 as a candidate drug for development.
Bay Area Stock B (02315.HK) announced that IDEAYA Biosciences (IDYA.US) has exercised its option to obtain the global exclusive license for the novel B7H3/PTK7 topoisomerase inhibitor effective payload bispecific antibody drug BCG034, which has similar pioneering potential as the company. The project has been nominated as a development candidate drug. Under the agreement, the company will receive an upfront payment and option exercise fee, additional development and regulatory milestone payments, commercial milestone payments, and net sales royalties, totaling up to 0.4065 billion US dollars, including up to 0.1 billion US dollars.
IDEAYA Biosciences: Strategic Initiatives and Growth Potential Reinforce Buy Rating
IDEAYA Licenses Biocytogen's Antibody Program for Cancer Treatment, Eyes FDA Submission in 2025
Biocytogen Announces IDEAYA's Nomination of Development Candidate IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise
Wall Street Analysts Predict an 81.88% Upside in IDEAYA Biosciences (IDYA): Here's What You Should Know
Stifel Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Cuts Target Price to $64
RBC Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $61
This Cognex Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
IDEAYA Biosciences Analyst Ratings
BTIG Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $62